Evidence map›Paper›PMID 20437980›Full record

ArticleClinical medicine (London, England)2010

How the NHS research governance procedures could be modified to greatly strengthen clinical research.

Richard Haynes, Louise Bowman, Kazem Rahimi, Jane Armitage

Abstract read
In one paragraph

Article in Clinical medicine (London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Richard HaynesClinical Trial Service Unit, University of Oxford.
Louise Bowman
Kazem Rahimi
Jane Armitage

Funding

Medical Research Council MC_U137686860
6 · The paper itself

Abstract

Randomised controlled trials are the gold standard for testing the efficacy and safety of health interventions, especially medications, and researchers in the U.K. are required to gain approval from ethics committees, the regulatory body (Medicines and Healthcare products Regulatory Agency) and local NHS research governance departments for such trials. Although research governance is important to reassure trial participants that their rights and interests are protected, current practice is impeding research and presents a genuine threat to the U.K. and to the NHS's ability to deliver high-quality evidence on which doctors can base clinical decisions and improve the delivery of care. This article discusses recent experience of running large-scale clinical trials and suggests measures that could improve the current situation.

Indexed as

Clinical GovernanceClinical Trials as TopicHumansRandomized Controlled Trials as TopicResearch Support as TopicState MedicineUnited Kingdom

Identifiers

PMID20437980
PMCPMC4952081

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.